Sign In
Buy SLDB
$8.30
-0.0300 (-0.360%)
At Close: Jun 22, 2026
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of “Moderate Buy” by Analysts
01:30am, Wednesday, 07'th Jan 2026
Shares of Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twelve research firms that are presently covering the company, Marketbeat.co
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 06'th Jan 2026
CHARLESTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Monday, 05'th Jan 2026
CHARLESTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ca
CHARLESTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of “Moderate Buy” by Brokerages
01:16am, Saturday, 13'th Dec 2025
Shares of Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the firm, Marketbeat.co
CHARLESTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 01'st Dec 2025
CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ca
– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich's ataxia – – FALCON Phas
- Non-exclusive license providing Solid's proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organizat
Solid Biosciences to Participate at Upcoming Investor Conferences
08:00am, Tuesday, 11'th Nov 2025
CHARLESTOWN, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines -
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 04'th Nov 2025
CHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ca
- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet wit
Solid Biosciences to Participate at Upcoming Investor Conferences
08:00am, Thursday, 30'th Oct 2025
CHARLESTOWN, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuro
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 01'st Oct 2025
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ca
